Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Oligodendroglioma × vocimagene amiretrorepvec × Clear all

Phase

Phase 1 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Astrocytoma 2 Recurrence 1 Oligodendroglioma 1

Interventions

Radiotherapy 2 vocimagene amiretrorepvec 1 Vincristine 1 Temozolomide 1 Radiation 1 Procarbazine 1 Lomustine 1 DNA 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04105374 2020-03-24

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡